{"name":"The TIMI Study Group","slug":"the-timi-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Unfractionated Heparin IV","genericName":"Unfractionated Heparin IV","slug":"unfractionated-heparin-iv","indication":"Acute coronary syndrome (unstable angina and myocardial infarction)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Unfractionated heparin SC","genericName":"Unfractionated heparin SC","slug":"unfractionated-heparin-sc","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Unfractionated Heparin IV","genericName":"Unfractionated Heparin IV","slug":"unfractionated-heparin-iv","phase":"marketed","mechanism":"Unfractionated heparin inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.","indications":["Acute coronary syndrome (unstable angina and myocardial infarction)","Pulmonary embolism treatment and prevention","Deep vein thrombosis treatment and prevention","Atrial fibrillation with thromboembolism risk","Cardiopulmonary bypass anticoagulation"],"catalyst":""},{"name":"Unfractionated heparin SC","genericName":"Unfractionated heparin SC","slug":"unfractionated-heparin-sc","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPa2JmNWhodnBGOGF2YUprU2F5ZVowU0RWTzdoWmFXa3BEUnpHbVlKTlVpbXM0czhvMHdOQnlRS0ptSjJyYldZQk5OX21lcFE0MDFMSU1ENEMxTVVYVjV3bTdWM3A5X3MzQW9lUjFqcGtySGF6TnlzbDR1d3dJaVVKV1FmTTdIb1F4ZjZtNjF6UUluMlhY?oc=5","date":"2025-11-10","type":"pipeline","source":"Medical Xpress","summary":"Triglyceride-lowering drug significantly reduce rate of acute pancreatitis in high-risk patients - Medical Xpress","headline":"Triglyceride-lowering drug significantly reduce rate of acute pancreatitis in high-risk patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQeExnQ0hhNG9OYUpsMjhsQ25jcHl2Z0FlTlZZRTA0TFBnYnl3aGIweFV6eHRPMFM3QV9TODUwbGtnU3RtMXo3XzN6Y3ZMVjNwZF9hOWtNeHg3OEIyVkVBNnFxeFQya0ZoZnJZMGZlbWNEOU1fNUF3eXEyZHNtTnNobmhQS3VHb182ODVtVjFvWEJUTW8xNFVjNDJUNFVMUXNDZVR4TVhfWXhZWUY2MFhISEYwV19tb28xQ01B?oc=5","date":"2025-11-08","type":"pipeline","source":"newsroom.heart.org","summary":"PCSK9 inhibitor reduced major CVD events in adults with no prior heart attack or stroke - newsroom.heart.org","headline":"PCSK9 inhibitor reduced major CVD events in adults with no prior heart attack or stroke","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOV0RjbXFWY3VVekdJRklxTkhfWWlfZndTczZkcXhwT2J1Wk1LSUJsaGZ1ellxNkhKNmhCUkRnR1hqVkhybEhHZm1MdmtjZzFuY0lVUktSbXZrSnFYVUdDekF3aTg5NTJ0anppbGY3Vlpxc3ZDTlM0dmVhX1djdzVtUEpPXzZsYlRpZkRQcUNFdlgwUGtvdWk3Y194eWV1SXBIRTM5M0RB?oc=5","date":"2025-09-04","type":"trial","source":"Medscape","summary":"Beta-Blockers Post-MI: Do More Data Clarify or Confuse? - Medscape","headline":"Beta-Blockers Post-MI: Do More Data Clarify or Confuse?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE45YXQzcEhiM0RncGJZX3k3ZUx4bTNsRGdMYl9ZYmRWYzZaTmtvcFZodHktZERHYkhvdDJpWVI4UXc1SThGZ2NVcEpYVWdNbVhNdGs4Zmg2S1pvNHJwZ2h0X29GeXhKLWNmamdWeE5SZnRjUQ?oc=5","date":"2025-09-03","type":"trial","source":"Clinical Trials Arena","summary":"Ionis reports topline outcomes from Phase III trials of olezarsen for sHTG - Clinical Trials Arena","headline":"Ionis reports topline outcomes from Phase III trials of olezarsen for sHTG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBXTTRqdXJVVDFVMGZXMzJsS0gzc1lQaU9vZHNtaHBQZkh4OTNMRUtiS3Baa2JWMUlsQ21CX1dQY2FNVjFtUUpUZkJwQ3F3MEdIYVlpOUx4SzFyQnQ5ZmgyVEdLRVVpelV0UjljdDhoaVpOY2c?oc=5","date":"2025-08-29","type":"trial","source":"American Heart Association Journals","summary":"Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patient","headline":"Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQSUZNUFFMT1R0V3E4Tzlud1hrb0Fqc1JKTGRDZ3N6SmtuMUlCdDU3bllVVndqdW5yYXFvcHFjbmt1cy1yTTk0UDFmdGJrYmdnbVBwZjVrYXJQS1pOUzVVR0YwSEZjUlZWRXZGYkdaTW5iTFZqWms3ak0zOU1VZVhURllZVDB3d2hmVENLN04tQllfdHNrTS14dUhxYkhIeEVLR0wxVjFfMnlEQQ?oc=5","date":"2025-05-21","type":"trial","source":"pharmatimes.com","summary":"Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia - pharmatimes.com","headline":"Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNNGgzd3RMZC00X0V0M0cxWHYzQkRFdE5CSjFxM0NleFJMOWUwc0hTX2lEZDZ2a2lQbERYekFkV1h0S21UMHluenphNW5NckVCZnNsUV9Va1VQUmJFUnlyS2xnODN2WVVUOHRqYm0tbzBpMExBR1hyWDBhVGxIQUluWFJyWm8?oc=5","date":"2025-05-20","type":"trial","source":"Clinical Trials Arena","summary":"Ionis reports positive data from study of olezarsen for hypertriglyceridemia - Clinical Trials Arena","headline":"Ionis reports positive data from study of olezarsen for hypertriglyceridemia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE0tVEdtMzRqWU1TcXFfbnFSeFNSM1lFQWVwUmEwWnJDTl9aeGhSTkRjblpaSG9UVzVGT2hFa3FHM1g3Y2lSODdOcDNYRnc0elE2Z21GTnBiVFE1SkFfV3Y0?oc=5","date":"2025-02-19","type":"trial","source":"nature.com","summary":"Long-term visit-to-visit blood pressure variability and risk of cardiovascular and bleeding events: insights from the ENGAGE AF-TIMI 48 trial - nature.com","headline":"Long-term visit-to-visit blood pressure variability and risk of cardiovascular and bleeding events: insights from the EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQcmJ2RkZ0ZloyOVJVNjZRZUFMRFV5Y3pnX2VmRzRvQUROQks5dWIzSUZhRGRwSmhEcWJkSUEwalRsN283MmRkdnlzTnBlSktYTWJ4TnFXaTZxUjUzRXZIcTh2cnRrRHVrRDZiYTVaQTRCelowaTd0UWdNNUhVVnBMQ25CZjJXMVVFSnBkSUxrM1dXbFN4LXNxbG9EYlNYb3RTN2JQTFJ1VWlOb3RRdU1UemN6RQ?oc=5","date":"2024-11-17","type":"trial","source":"Pharmacy Times","summary":"Reduced Bleeding With Abelacimab Could Transform Atrial Fibrillation Treatment - Pharmacy Times","headline":"Reduced Bleeding With Abelacimab Could Transform Atrial Fibrillation Treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQdFFXZEpWb2RTN2NLQnJvT1BOeFlycl9tR25MbklJdlczc29ScWotcVl2Z2NHUGs0R3RDLUpoM0RMR2h2TTVMZWdJSXBPWkl0R01DYm5JWXFYeGZ2NG0yQkRiNHVVdXNDMzIxTFVxQ0FnNmEydTZGck5WSWVKaVo2OG1MTV9oRGk1Zi11eTVYV1pLNkdOVUhRM3pn?oc=5","date":"2023-01-05","type":"trial","source":"TCTMD.com","summary":"Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees - TCTMD.com","headline":"Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNaUl4MEw3a05UVzZvYUFDdXVrdFR6bUNiZTRCMFNlcUZ6dF9Kbml1U0FIdHN0emYtZmF5X3RYTmcyRzNJcnlIZmZWZU5ndVBXVVFDcFFkWFVzVHRiZDdyUllxM1NVUGFVRk9wSkJ5Uy1lNUJRc1V4VUhFT0lsUWNlVDRVLXZRUTI3ei1ZcTBiT05xc193eXlBZlc4YXVwZVQzWkZDd29LSWNmVktGTEtPajBCcHRfcXl5TVhhbHU0MnM?oc=5","date":"2022-09-08","type":"trial","source":"dicardiology.com","summary":"FOURIER-OLE Trial Finds that Long-term Use of Evolocumab Further Reduced Cardiovascular Events - dicardiology.com","headline":"FOURIER-OLE Trial Finds that Long-term Use of Evolocumab Further Reduced Cardiovascular Events","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9xNV93SzhvRDNUbm1zU3RTdnBod3ZOcDY4WHVmREZ6NC16dGdHV1g3WWNTREdQcGFZdmozdkVrRVNuT3B0UTBUR3FaUXBoVHVpXzVITnZCZ0hveFRUYVRz?oc=5","date":"2019-09-19","type":"pipeline","source":"NEJM","summary":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction - NEJM","headline":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}